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Abstract
The estimates of global incidence and prevalence of 
non-alcoholic fatty liver disease (NAFLD) are worrisome, 
due to the parallel burden of obesity and its metabolic 
complications. Indeed, excess adiposity and insulin 
resistance represent two of the major risk factors for 
NAFLD; interestingly, in the last years a growing body 
of evidence tended to support a novel mechanistic 
perspective, in which the liver is at the center of a 
complex interplay involving organs and systems, other 
than adipose tissue and glucose homeostasis. Bone and 
the skeletal muscle are fat- free tissues which appeared 
to be independently associated with NAFLD in several 
cross-sectional studies. The deterioration of bone mineral 
density and lean body mass, leading to osteoporosis and 
sarcopenia, respectively, are age-related processes. The 
prevalence of NAFLD also increases with age. Beyond 
physiological aging, the three conditions share some 
common underlying mechanisms, and their elucidations 
could be of paramount importance to design more 
effective treatment strategies for the management 
of NAFLD. In this review, we provide an overview on 
epidemiological data as well as on potential contributors 
to the connections of NAFLD with bone and skeletal 
muscle. 
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Core tip: Novel epidemiological findings open new 
avenues for a thorough understanding of the patho-
genesis of non-alcoholic fatty liver disease (NAFLD). 
Liver appears to participate in a fascinating cross- talk 
with fat-free tissue, mainly bone and skeletal muscle. 
The identification of contributors other than the classic 
roles played by excess fat and insulin resistance may 
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be relevant for the design of more effective treatment 
strategies for NAFLD. 
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INTRODUCTION
In the last decades, a wealth of studies have focused 
on non-alcoholic fatty liver disease (NAFLD), given 
that the rising prevalence of this clinical condition 
has paralleled the obesity epidemic in Western and 
developing countries[1,2]. The intrahepatic triglyceride 
accumulation is the hallmark of NAFLD[3]; energy 
imbalance and insulin resistance are considered the 
most relevant determinants leading to ectopic fat 
deposition in the liver, and NAFLD has been described 
as the hepatic manifestation of the metabolic syn-
drome[3,4]. Hence, evidence regarding NAFLD is 
undoubtedly strictly related to excess adiposity and 
its metabolic consequences[2-4]. However, in recent 
years, NAFLD has been associated to diseases and 
clinical conditions which typically have a natural 
history that is independent of obesity, such as 
osteoporosis and the decline of lean body mass, 
namely sarcopenia[5,6]. Similar to osteoporosis 
and sarcopenia, which are notably linked to age-
related processes[7], the prevalence of NAFLD also 
tends to increase with aging in men and in both 
premenopausal and postmenopausal women[8,9]. 
Furthermore, the association between fatty liver and 
poor bone mineralization has been also revealed in 
the pediatric population[5], expanding the constellation 
of mechanistic hypotheses other than the known 
potential contributors characterizing the aging process 
(e.g., changes in sex steroids)[8,10]. Therefore, NAFLD 
appears to be at the center of an intriguing cross- talk 
involving fat-free tissues, in a new fascinating scenario 
in which obesity could be only marginally present. In 
the extant studies, the relationships between NAFLD 
and bone health, as well as between NAFLD and 
sarcopenia, have been separately examined. The aim 
of the present review is to summarize epidemiological 
evidence and potential underlying mechanisms in the 
complex interplay among NAFLD, bone, and skeletal 
muscle. Relevant peer- reviewed journal articles 
published in English were identified in the MEDLINE 
database (the last search was conducted on August 
31, 2016); different combinations of the following 
search terms were used: “nonalcoholic fatty liver 
disease”, “bone”, “skeletal muscle mass”, “lean body 
mass”. 
Also the following exclusion criteria were used: 
any paper dealing with viral or autoimmune hepatic 
disease, inherited metabolic disorders, excessive 
alcohol intake; any paper including the definition 
of NAFLD based on clinical chemistry data only 
(e.g., elevated aminotransferase levels); any paper 
on sarcopenia associated to cancer cachexia or 
neurological diseases, inflammatory or autoimmune 
diseases, corticosteroids for systemic use; any paper 
including bedridden subjects; any paper concerning 
osteoporosis as secondary disease; any paper in which 
fractures and not bone mineral density (BMD), were 
the main outcome; any paper evaluating markers of 
bone turnover without data on BMD; and any study 
conducted in animals. Review articles and secondary 
data analyses, letters in response to published articles, 
editorials, commentaries and conference abstracts 
were excluded.
NAFLD AND BONE MINERAL DENSITY
Most studies dealing with BMD in subjects with fatty 
liver were conducted in the Asian population, and liver 
ultrasonography was the most used method for the 
diagnosis of NAFLD. BMD was assessed by dual energy 
X-ray absorptiometry (DXA) in all studies, but different 
sites of the skeleton, or whole body BMD, were 
examined (Table 1)[11-22]. The association between 
NAFLD and decreased BMD has been reported in 
both genders, and also confirmed in children and 
adolescents, in the majority of the studies, with few 
exceptions[13,16,20]. 
Xia et al[11] reported a negative association between 
NAFLD and any site of the skeleton examined in 
Chinese men and postmenopausal women aged 46-93 
years. Similarly, Cui et al[12] described a negative 
association between NAFLD and BMD (as average 
of BMD at the femoral neck, hip, and lumbar spine) 
in Chinese men and postmenopausal women (aged 
40-70 years). However, both genders with NAFLD 
showed lower BMD at the hip than controls, whereas 
no difference was found at the lumbar level. In a 
large Korean cohort including men aged 40 years 
and older, and postmenopausal women, Lee et al[13] 
observed a negative association between NAFLD and 
the femoral neck BMD in men, whereas a positive 
relationship emerged between NAFLD and lumbar 
spine BMD in women. Moon et al[14] reported that 
a negative association between NAFLD and lumbar 
spine BMD was present in postmenopausal, but not 
premenopausal women. However, in these studies 
liver ultrasound was used to diagnose NAFLD. It is well 
known that sonography is highly operator-dependent, 
and has limited repeatability and reproducibility 
because it evaluates liver fat content on the basis of 
subjective qualitative features of liver echogenicity[23]. 
In addition, just a few studies examined thoroughly 
multiple sites or whole body bone mineral density. 
Bhatt and coll. assessed BMD in different skeletal 
segments, and surprisingly, found higher BMD values 
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in some bone sites (namely, trunk, pelvis, spine, and 
also whole body BMD) in adult subjects with NAFLD 
compared to controls[16]. In this study, participants 
with NAFLD had a higher BMI and a higher body fat 
than controls, and any adjustments for either BMI 
or body fat were not considered in the comparison 
of BMD between groups: this may account for the 
discrepant results obtained[16]. Currently it is unclear 
if the presence of NAFLD is associated to a higher 
susceptibility to bone mass deterioration in any specific 
segment of the skeleton, and this research question, 
together with a more in-depth investigation of gender 
differences, needs to be addressed in future studies. 
However, evidence from pediatric studies, in which 
NAFLD was biopsy-proven, suggests that the effects 
of the interrelationship between fatty liver and bone is 
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Table 1  Studies exploring the association between non-alcoholic fatty liver disease and bone mineral density
Ref. Study population and sample size Race/ethnicity NAFLD assessment Skeleton: 
segments
Main findings: BMD
Xia et al[11], 
2016 
Elderly men (n = 755) and 
postmenopausal women (n = 904) 
divided into quartiles of liver fat 
content (LFC)
Chinese Liver quantitative 
US
Lumbar spine, 
hip, whole body
BMD in any skeletal segment was lower in 
the highest LFC quartile compared to the 
lowest quartile. LFC inversely correlated 
with BMD (all skeletal segments)
Cui et al[12], 
2013
Men with NAFLD (n = 46) vs male 
controls (n = 53); postmenopausal 
women with NAFLD (n = 73) vs 
female controls (n = 52)
Chinese Liver US Lumbar spine, 
right hip, femoral 
neck
Lower BMD at the right hip in participants 
with NAFLD than controls (in both 
genders); lower BMD at the femoral neck 
in men with NAFLD vs controls. Negative 
association between NAFLD and BMD
Lee et al[13], 
2016 
Men with NAFLD (n = 1288) vs male 
controls (n = 2018); postmenopausal 
women with NAFLD (n = 1217) vs 
female controls (n = 2112)
Korean Liver US Lumbar spine and 
femoral neck
Negative association between femoral 
neck BMD and NAFLD in men; positive 
correlation between lumbar spine BMD 
and NAFLD in postmenopausal women
Moon et al[14], 
2012 
Premenopausal women with 
NAFLD (n = 162) vs controls (n 
= 54), and postmenopausal with 
NAFLD (n = 102) vs controls (n = 
163)
Korean Liver US Lumbar spine Higher BMD in the control group than 
postmenopausal women NAFLD; 
NAFLD negatively associated with BMD 
in postmenopausal women, but not 
premenopausal women
Purnak et al[15], 
2012 
Men (n = 52) and women (n = 50) 
with NAFLD vs healthy men (n = 
28) and women (n = 26)
Caucasian Liver US Femur (neck, 
trochanter, 
intertrochanteric 
region and total 
femur) and 
lumbar spine
Lower lumbar spine and femoral neck 
BMD Z-scores in women with high ALT 
levels
Bhatt et al[16], 
2013 
Men (n = 129) and women (n = 33) 
with NAFLD vs controls (men, n = 
109; women, n = 64)
Indian Liver US Trunk, pelvis, 
spine, whole body
Higher BMD values in NAFLD subjects 
than controls
Yang et al[17], 
2016 
Men with NAFLD (n = 249) vs male 
controls (n = 610)
Korean Liver US Right Hip NAFLD negatively associated with right-
hip BMD
Pacifico et al[18], 
2013 
Obese children with NAFLD (boys, 
n = 24, and girls, n = 20) vs obese 
controls (boys, n = 24, and girls, n = 
20)
Caucasian MRI + liver biopsy Lumbar spine and 
whole body
Lower lumbar BMD Z-score in NAFLD 
children than controls. Negative 
association of lumbar BMD and whole-
body BMD Z-scores with NASH
Pardee et al[19], 
2012 
Obese children( 10-17 yr) with (n = 
38) or without (n = 38) NAFLD
Mixed (89.5% 
Hipanic, 10.5% 
non-Hispanic, 
White)
Liver biopsy Whole body Lower whole body BMD Z-score in 
children with NAFLD than children 
without NAFLD. Lower whole body 
BMD Z-score in children with NASH than 
children without NASH
Chang et al[20], 
2015 
Obese children and adolescents with 
NAFLD (n = 15) vs obese children 
and adolescents with NASH (n = 47) 
vs controls (n = 32)
Korean Liver US (NAFLD); 
liver US + 
elevated serum 
aminotransferase 
levels (NASH)
Arm, leg, trunk, 
whole body
Age-matched BMD Z-scores were not 
different between groups
Pirgon et al[21], 
2011 
Obese children with NAFLD (boys, 
n = 19, and girls, n = 23) vs obese 
children (boys, n = 18, and girls, n = 
22) and lean children (boys, n = 15, 
and girls, n = 15)
Caucasian 
(Turkish)
Liver US Lumbar spine Lower lumbar BMD-SDS in obese 
adolescents with NAFLD compared 
with obese and lean adolescents without 
NAFLD
Campos et al[22], 
2012 
Obese adolescents with NAFLD (n 
= 18) vs obese adolescents without 
NAFLD (n = 22)
Brazilian Liver US Whole body Obese adolescents with NAFLD had a 
significantly lower values of BMC than 
their counterparts without NAFLD. No 
differences in BMD Z-scores
BMC: Bone mineral content; BMD-SDS: Bone mineral density-standard deviation score; BMD: Bone mineral density; LFC: Liver fat content; MRI: Magnetic 
resonance imaging; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; US: Ultrasound; ALT: Alanine aminotransferase.
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the higher quartiles. Interestingly, this association 
was maintained even after adjustment for potential 
confounders such as age, sex, physical activity level, 
homeostasis model assessment of insulin resistance 
(HOMA-IR), C-reactive protein, and vitamin D levels. 
In a different cohort of Korean subjects with a biopsy-
proven diagnosis of NAFLD, Koo et al[25] found that the 
prevalence of sarcopenia [defined by the appendicular 
skeletal muscle mass divided by body weight or 
normalized to body mass index (BMI)], increased 
according to NAFLD histological grades (steatosis 
and ballooning) and fibrosis stage. In addition, 
the odds ratio of having NASH was increased in 
sarcopenic subjects compared to their nonsarcopenic 
counterparts, independent of obesity and HOMA-IR. 
In the remaining studies, the assessment of NAFLD or 
liver fibrosis was based on the calculation of surrogate 
indices (Table 2). In a large population- based study, 
namely the KHANES 2008-2011, Lee et al[26] observed 
an approximately two-fold higher risk of liver fibrosis 
in sarcopenic subjects with NAFLD, independent of 
obesity and insulin resistance. Analogous observations 
were provided by other studies carried out in Korean, 
Japanese and Italian cohorts[27-31], showing that 
the relationship linking NAFLD and sarcopenia was 
independent of the classic risk factors such as obesity, 
insulin resistance or other metabolic covariates. 
Notably, the aforementioned studies included mainly 
middle-aged and elderly participants. As such, the 
reciprocal influence of NAFLD and skeletal muscle in 
the first decades of life remains to be clarified. 
POTENTIAL MECHANISMS UNDERLYING 
THE INTERPLAY BETWEEN NAFLD, 
BONE, AND SKELETAL MUSCLE
Growth hormone/insulin-like growth factor 1 axis
The growth hormone/insulin-like growth factor 1 
(GH/IGF1) axis is involved in protein metabolism 
in the skeletal muscle as well as bone growth and 
remodeling[33,34]. The age-related decline of the 
somatotropic axis activity, namely the somato-
pause, represents an important determinant of the 
development of osteoporosis and sarcopenia[34]. 
Recent evidence highlights the crucial role of IGF1 
signaling in the cross-talk linking striated muscle and 
bone[35]. Furthermore, NAFLD is a frequent comorbidity 
observed in patients with GH deficiency, with a more 
rapid progression to NASH[36]. Several studies have also 
reported decreased levels of IGF1, that is the major 
mediator of GH action, in subjects with NAFLD[37]. GH 
and IGF1 influence carbohydrate and lipid metabolism, 
with opposite actions: IGF1 stimulates glucose 
uptake, favoring insulin signaling, whereas GH induces 
lipolysis, determining insulin resistance mediated 
by elevated free fatty acid levels[38,39]. However, the 
association between NAFLD and IGF1 appears to be 
independent of insulin resistance[40]. Sumida et al[41] 
already present in the first decades of life, and whole 
body bone mass seems to be affected[18,19]. Pacifico 
et al[18] evaluated lumbar spine BMD and whole body 
BMD in obese children with fatty infiltration of the liver, 
as assessed through MRI (two-point Dixon method) 
and liver biopsy. Compared to controls, children with 
NAFLD had lower whole body BMD and lumbar spine 
BMD; similarly, whole body BMD Z-score and lumbar 
segmental BMD Z-score were significantly lower 
according to histological staging. The association 
between NAFLD and BMD was maintained even after 
adjustment for fat mass or high-sensitivity C-reactive 
protein levels. Conversely, Chang et al[20] described 
no difference in age-matched BMD Z-scores in Korean 
children with simple steatosis or NASH, compared to 
controls; in that study, the diagnosis of NAFLD was 
based on liver ultrasonography, and NASH was defined 
as the presence of elevated transaminase levels in 
children with NAFLD. These observations need to be 
consolidated by further research in larger cohorts, 
using gold-standard methods for the evaluation of 
fatty liver. 
NAFLD AND SKELETAL MUSCLE
Growing interest has been directed to the involvement 
of skeletal muscle mass in chronic liver disease, 
especially in cirrhosis. The decline in lean body mass, 
namely sarcopenia, has been recognized as one 
of the comorbidities accompanying liver cirrhosis, 
likely related to malnutrition occurring in cirrhotic 
patients[24]. Beyond chronic liver disease of viral or 
auto-immune origin, several studies have described 
the phenotype of sarcopenia in subjects with NAFLD 
(Table 2)[25-31]. Evidence concerning the deterioration 
of skeletal muscle in NAFLD is scarce, and data from 
pediatric studies are lacking, due to several reasons. 
First, sarcopenia is an age-related process, with 
prevalence increasing in late life[7]. However, the 
coexistence of risk factors such as obesity and physical 
inactivity may be responsible for a more precocious 
onset of this clinical condition. Second, contrary 
to osteoporosis and reduction of the BMD in the 
pregeriatric population, universally accepted criteria 
for the diagnosis of sarcopenia are lacking and are still 
under debate[32]. In the extant studies investigating 
the relationship between sarcopenia and NAFLD, 
the skeletal muscle mass was assessed by DXA or 
bioimpedance analysis (BIA), and different indices of 
sarcopenia were used. The majority of studies relied 
on the use of surrogate indices to identify NAFLD and 
fibrosis in NAFLD. Moreover, the Asian population has 
been mainly investigated, whereas evidence from 
other ethnic groups is scarce to date. In the Korean 
Sarcopenic Obesity Study, Hong et al[6] demonstrated 
that participants in the lowest skeletal muscle index 
quartile exhibited a higher odds ratio of having 
NAFLD (defined by the liver attenuation index from 
abdominal computed tomography) than subjects in 
Poggiogalle E et al . NAFLD and fat-free tissues
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found that IGF1 levels and IGF1-standard deviation 
score (SDS) values were lower in Japanese subjects 
with NAFLD at the histological examination when 
compared to controls; moreover, IGF1-SDS values 
were associated with the histological severity of 
NAFLD, independent of insulin resistance. Similarly, 
in a large population- based study, Völzke et al[42] 
described an association between low IGF1 and IGF1/
IGFBP3 ratio and liver hyperechogenicity, independent 
of BMI and diabetes. Though the prevalence of hepatic 
steatosis, and the deterioration of lean body mass 
and BMD tend to increase with age[7,8], paralleling the 
somatopause, the GH/IGF1 axis affects the liver, the 
skeletal muscle and bone health even in earlier stages 
of life. In fact, IGF1 is known to stimulate longitudinal 
bone growth[43], and recently an analogous action has 
been attributed also to GH, independent of IGF1[44]. A 
robust correlation between IGF1 levels and bone mass 
has been shown to occur in early pubertal stages in 
both genders[45]. Cianfarani et al[46] found that IGF1 
levels were associated with NAFLD activity score and 
histological patterns in obese children with biopsy-
proven NAFLD. A recent study by Cabrera and coll. 
shed light on the underlying mechanisms linking IGF1, 
NAFLD and sarcopenia[47]. In mice NAFLD was induced 
by an American Lifestyle-Induced Obesity Syndrome 
(ALIOS) diet model, based on a Western dietary 
pattern combined to fructose excess. Muscle fiber size 
and muscle strength, as well as IGF1 levels decreased 
in animals with diet-induced NAFLD. Interestingly, 
the phenotypic aspects of sarcopenia were observed 
prior to the development of liver fibrosis, indicating 
that they could occur in early stages of NAFLD natural 
history[47]. 
Vitamin D deficiency 
Vitamin D deficiency has been postulated to play a role 
in the pathogenesis of NAFLD. Two recent quantitative 
Table 2  Studies exploring the association between non-alcoholic fatty liver disease and skeletal muscle mass
Ref. Study population and sample size Race/
ethnicity
NAFLD 
assessment
Skeletal muscle 
mass assessment
Main findings:
skeletal muscle
Hong et al[6], 
2014 
Men (n = 32) and women (n = 96) with 
sarcopenia vs men (n = 135) and women (n = 
189) without sarcopenia
Korean LAI DXA: Increased ORs of NAFLD in individuals 
with SMI value in the lower quartiles-SMI = SMM/
weight (%)
Koo et al[25], 
2016 
Adults with NAFLD (n = 117) vs adults with 
NASH (n = 123) vs controls (n = 69)
Korean Liver biopsy, 
Fibroscan
BIA: Lower ASM (%) and ASM/BMI in 
NAFLD and NASH than controls; higher 
prevalence of sarcopenia in NAFLD and 
NASH groups than control group
-ASM (kg)
-ASM/weight (%)
-ASM/BMI
Lee et al[26], 
2015 
Men (n = 5617) and women (n = 9515) 
divided into four groups: sarcopenic obese 
(n = 2455) vs non-sarcopenic obese subjects 
(n = 2198); sarcopenic non-obese (n = 2004) vs 
non-sarcopenic non-obese subjects (n = 8475)
Korean For NAFLD: 
HSI, CNS
DXA: Inverse correlation between all indices 
of NAFLD and SMI
For fibrosis: 
BARD, FIB-4
-ASMI = ASM/
weight (%)
Increased ORs of NAFLD and advanced 
fibrosis in subjects with sarcopenia
Hashimoto et 
al[27], 2016 
Diabetic men with NAFLD (n = 58) vs 
controls (n = 21), and diabetic women with 
NAFLD (n = 39) vs controls (n = 27)
Japanese CAP BIA: Negative association between CAP and 
SMI in men; no significant association in 
women
FIB-4 -SMM (kg)
-SMI = SMM/
weight (%)
Moon et al[28], 
2013 
Low FLI group (men = 1641, and women, n 
= 1180) vs intermediate FLI group (men, n = 
2600, and women, n = 2296) vs high FLI group 
(men, n = 1052, and women, n = 796)
Korean FLI BIA: Lower SMI in the high FLI group and 
the intermediate FLI group than the low 
FLI group. Negative correlation between 
FLI and SMI, and between FLI and SVR. 
The highest SVR quartile had a lower 
OR for FLI ≥ 60
-SMI = SMM/
weight (%)
-SVR = SMM/VFA
Kim et al[29], 
2016 
FLI ≥ 60 group (men, n = 208, and women, n 
= 181) vs FLI < 60 group (men, n = 976, and 
women, n = 2374)
Korean FLI DXA: Lower SMI in the high FLI group than 
the low FLI group in both genders. 
Increased ORs for FLI-defined NAFLD 
in men and women with low SMI
-ASM (kg)
-SMI = ASM/
weight (%)
Lee et al[30], 
2016 
Men (n = 1241) and women (n = 1520) with 
NFLS-based NAFLD divided into two 
groups: sarcopenic subjects (n = 337) v. non-
sarcopenic subjects (n = 2424)
Korean For NAFLD: 
NLFS, 
CNS,HSI;
DXA: Higher NFS, FIB-4, and Forns index 
in the sarcopenic group that the non-
sarcopenic group; negative association 
of SI with NFS, FIB-4, and Forns indexFor fibrosis: 
NFS, FIB-4, 
Forns index
-SI = ASM/BMI
Poggiogalle et 
al[31], 2016 
Obese men (n = 81) and women (n = 346) 
divided into 2 groups: FLI 20 ≤ FLI < 60 (n 
= 61) and FLI ≥ 60 (n = 359) (FLI ≤ 20 in 7 
subjects only, excluded from the analysis)
Caucasian 
(Italian)
FLI DXA: Positive association between FLI and 
TrFM/ASM ratio (indicating high 
visceral adiposity and low appendicular 
muscularity)
-TrFM/ASM ratio
ASM: Appendicular skeletal mass; ASMI: Appendicular skeletal mass index; BMI: Body mass index; CAP: Controlled attenuation parameter; CNS: 
Comprehensive NAFLD score; CT: Computed tomography; FLI: Fatty liver index; HIS: Hepatic steatosis index; LAI: Liver attenuation index; NAFLD: Non-
alcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; NFS: NAFLD fibrosis score; SI: Sarcopenia index; NLFS: NAFLD liver fat score; SMI: 
Skeletal muscle index; SMM: Skeletal muscle mass; SVR: Skeletal muscle to visceral fat ratio; TrFM: Truncal fat mass; VFA: Visceral fat area.
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meta-analysis (including twenty-three and nine 
studies, respectively) concluded that 25(OH)D levels 
were lower in subjects with NAFLD or NASH than in 
individuals without fatty liver[48,49]. If cross-sectional 
studies support the potential influence of vitamin D 
status on NAFLD[50], limited evidence exists proving 
the effectiveness of vitamin D supplementation in 
NAFLD patients[51,52]. However, findings from animal 
models revealed that vitamin D interferes with the 
activation of hepatic stellate cell, which are responsible 
for collagen deposition and extracellular matrix 
remodeling, leading to fibrosis[53]. Vitamin D seems 
to inhibit hepatic stellate cell proliferation[53], and 
clinical trials are needed to demonstrate that vitamin 
D supplementation could slow down the progression 
from NAFLD to NASH. Vitamin D is well known to exert 
pleiotropic effects. Vitamin D plays a relevant role in 
bone homeostasis: vitamin D deficiency determines 
secondary hyperparathyroidism and accelerated bone 
turnover[54]. Inadequate vitamin D levels have been 
reported in subjects with osteoporosis, even if only 
modest beneficial effects of vitamin D supplementation 
have been shown in fracture prevention[55]. In the 
last years mounting interest has been addressed to 
vitamin D action in skeletal muscle. Reduced vitamin D 
levels have been associated with sarcopenia, disability, 
and falls in the elderly[56,57]. In adults with vitamin 
D deficiency, histological alterations in muscle fiber 
composition and diameter have been described[58]. In 
disagreement with the above mentioned data, among 
the studies included in the present review, Hong et 
al[6] found no significant association between 25(OH)D 
levels and skeletal muscle index or liver attenuation 
index in Korean men and women. Methodological 
issues exist in the studies which explored vitamin D 
status, especially related to seasonality, variability in 
sun exposure, coexistence of obesity and physical 
inactivity. The presence of these potential confounders 
limits the interpretation of the available data. 
Osteocalcin
Osteocalcin is a bone-derived hormone, mainly pro-
duced by the osteoblasts, and is a non-collagenous 
matrix protein. Osteocalcin is considered as a serum 
biomarker of bone formation. In a number of studies 
a negative association has been described between 
serum osteocalcin levels and decreased bone mineral 
density in postmenopausal women[59,60]. Emerging 
evidence from animal and human studies unveiled 
that osteocalcin is involved in many homeostatic 
mechanisms other than those specific for bone 
health[61,62]. Notably, osteocalcin is able to interfere with 
energy and glucose metabolism, modulating pancreatic 
beta-cell activity. Undercarboxylated osteocalcin is the 
active isoform of the hormone, responsible for inducing 
insulin secretion and favoring insulin sensitivity in 
skeletal muscle and adipose tissue[61,62]. Accumulating 
evidence suggests that osteocalcin is also involved in 
liver disease; low serum osteocalcin levels have been 
related to NAFLD. In a case-control study, Yilmaz 
and coworkers found that osteocalcin was inversely 
associated with histological features of NAFLD[63]. 
Moreover, this inverse association linking osteocalcin 
and NAFLD has been also reported in male and female 
participants with normal bone mineral density[64-66]. In 
an experimental model of diet- induced NAFLD, the 
administration of osteocalcin was demonstrated to be 
effective in reversing metabolic changes and reducing 
markedly hepatic triglyceride content, suggesting a 
protective role of osteocalcin in NAFLD development[67]. 
Interestingly, osteocalcin has been shown to play a 
crucial role also in the inter-organ cross-talk between 
the skeleton and skeletal muscle. Osteocalcin signaling 
in myofibers seems to be an important mediator 
of metabolic adaptive mechanisms to exercise[68]. 
In addition, recently Mera and coll. showed that in 
mice exogenous osteocalcin administration promoted 
protein synthesis in myotubes, preventing the age-
related muscle loss[69]. Further evidence is required 
to establish if osteocalcin may represent a suitable 
candidate for counteracting muscle wasting and liver 
fat infiltration. 
Insulin resistance
NAFLD is known to be the hepatic manifestation of the 
metabolic syndrome, due to the remarkable effects 
of insulin resistance in the pathogenesis of hepatic 
steatosis[70]. Intrahepatic lipid accumulation has been 
related to the deterioration of insulin sensitivity at the 
level of liver, skeletal muscle, and adipose tissue[71]. 
Furthermore, the presence of NAFLD predicts the 
risk of developing type 2 diabetes, independent of 
age and obesity[72]. Furthermore, insulin resistance 
is a key factor also in anabolic processes taking 
place in the skeletal muscle and bone. The skeletal 
muscle is the major target tissue of insulin action[73]. 
On one hand, insulin resistance interferes with the 
effectiveness of protein synthesis, leading to the age-
related reduction of lean body mass[74]. In nondiabetic 
elderly subjects, Guillet et al[75] reported that insulin 
ability to counteract whole body protein break down 
was decreased. On the other hand, the presence of 
reduced lean mass can further favor the development 
of insulin resistance[74]. In vitro and in vivo studies 
demonstrated that insulin plays an important role 
in bone homeostasis. Insulin promotes osteoblast 
proliferation and differentiation, the generation of 
anabolic signals and collagen synthesis, influencing 
microarchitecture and mechanical properties of 
bone[76]. A complex connection exists between bone 
metabolism and insulin resistance, with the frequent 
overlap of insulin resistance and excess adiposity 
being the major confounding factor. Due to the 
increased mechanical load on the skeleton, obesity 
appeared to confer protection against bone mass 
deterioration. In addition, bone turnover seemed to 
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be lower in subjects with the metabolic syndrome and 
type 2 diabetes[77]. Even if evidence is not conclusive, 
especially for the prevention of fragility fractures[78], 
this assumption has been weakened by a number of 
studies in which the relationship between metabolic 
syndrome and bone outcomes, such as bone strength 
or areal BMD, became negative in models adjusted 
for BMI[79]. In fact, several studies reported a negative 
association between insulin resistance and bone 
mineral density as well as bone strength indices and 
markers of bone formation[80-82]. Novel findings from 
animal studies unveiled that bone represents a site 
of insulin resistance, and osteoblasts are primarily 
involved in insulin signaling in bone. In more detail, 
in mice fed a high-fat diet, insulin resistance in 
osteoblasts was responsible for the reduced production 
of osteocalcin, which in turn affected detrimentally 
whole body insulin sensitivity[83,84]. Furthermore, in 
a model of high-fat diet induced obesity in rats, the 
development of insulin resistance led to reduced 
osteoblast proliferation and differentiation, and 
increased osteoblast apoptosis, resulting in decreased 
jaw bone density[85].
Chronic inflammation
A proinflammatory milieu represents another 
common soil favoring the development of the three 
conditions examined in the present review. Systemic 
inflammation is one of the major actors in the 
progression from NAFLD to NASH[86]. Liver resident 
cells, like hepatic stellate cells, Kupffer cells, and 
dendritic cells, generate pro-inflammatory signals 
involved in the cascade leading to cell death[86]. In 
addition, tumor necrosis factor-alpha (TNF-a) is 
another relevant mediator and inducer of hepatocyte 
death[87]. Also in aged skeletal muscle, TNF-alpha 
signaling is involved in the activation of apoptosis, 
leading to muscle fiber loss and sarcopenia[88]. Though 
the role of proinflammatory cytokines, IL-6, in protein 
breakdown in skeletal muscle is controversial[89,90], 
epidemiological evidence underpins the relationship 
between chronic low-grade inflammation and age-
related sarcopenia[91]. The interplay between TNF-
alpha and the RANKL/RANK/osteoprotegerin system 
is crucial for the modulation of osteoclast activity and 
bone resorption and remodeling[92]. Recently, reduced 
osteoprotegerin levels have been described in NAFLD, 
independent of potential confounders[93,94]. Taken 
together, these observation emphasize the connections 
linking immune response, inflammation, and bone 
physiology to NAFLD. 
Physical inactivity
Sedentariness is a well- known risk factor for weight 
gain and the consequences related to excess fat, 
including the onset of fatty liver[95]. Indeed, lifestyle 
interventions, combining dietary interventions and 
physical activity, have been demonstrated to be 
beneficial in terms of liver fat reduction, due to weight 
loss. Interestingly, mounting evidence supports an 
exercise effect and a physical fitness role per se in the 
pathophysiology of NAFLD[96]. In fact, based on pooled 
data from six studies, a recent meta-analysis revealed 
that exercise alone (vs non-exercise control, without 
any dietary intervention) was sufficient to determine 
a significant decrease of the intrahepatic lipid content, 
even in the absence of weight change, or minimal 
weight loss[97]. 
Physical inactivity represents also a well- established 
risk factor for both sarcopenia and osteoporosis. The 
lack of physical activity favors the decline of lean 
body mass, triggering a vicious cycle leading to both 
progressive inactivity and sarcopenia[98]. Similarly, 
physical activity is recognized as a relevant factor 
in promoting bone health across the lifespan[99,100]. 
According to the mechanostat theory, bone and skeletal 
muscle are connected by mechanical interactions. In 
the last years, skeletal muscle and bone have been 
demonstrated to act as endocrine organs, producing 
several factors responsible for this intriguing inter-organ 
cross-talk[101]. 
Among a number of factors involved in the above 
mentioned interplay, irisin is a recently described 
hormone- like myokine. Plasma irisin levels increase 
in response to exercise; moreover, irisin is able to 
increase energy expenditure. Irisin autocrinally 
modulates some metabolic functions in the skeletal 
muscle, and it also exerts endocrine effects on 
adipocytes and osteoblasts. In fact irisin can induce 
browning of white adipose tissue, and can regulate 
the expression of osteogenic genes as well as it is able 
to induce differentiation of osteoblasts[102]. Zhang et 
al[103] reported that circulating irisin was negatively 
associated with intrahepatic triglyceride content in 
Chinese obese adults with NAFLD, independent of 
other metabolic factors. Due to the pleiotropic effects 
on energy metabolism, glucose homeostasis, insulin 
resistance, and obesity, irisin may represent a pivotal 
mediator in the complex communication among the 
liver, skeletal muscle and bone[104,105].
CONCLUSION
Emerging evidence supports the crucial role played 
by new contributors in the pathogenesis of NAFLD 
in a complex inter-organ communication, widening 
the classic paradigm centered on insulin resistance 
and excess fat. In this emerging perspective, fat- 
free tissues like bone and skeletal muscle appear to 
be relevant actors. Though the novel findings are 
fascinating, the roles of fat-free tissues, independent 
of obesity and classic risk factors for NAFLD, need to 
be further investigated. More rigorous methods for the 
diagnosis of NAFLD and sarcopenia should be used. 
The extant evidence needs to be confirmed in different 
races and ethnicities, and further research should be 
prompted in order to narrow the gap in the literature, 
especially with regard to the connection between 
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NAFLD and skeletal muscle in the early stages of the 
aging process. 
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